Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Licenses Stem Cell Patents

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis today said that it has licensed intellectual property covering induced Pluripotent Stem Cells (iPSCs) from iPS Academia Japan.

The non-exclusive licensing deals cover research conducted by Shinya Yamanaka of the Center for iPS Cell Research and Application at Kyoto University in Japan. iPS Academia Japan is an affiliate of Kyoto University established in 2008 to manage IP covering iPSC technologies.

The agreements allow Cellectis and its affiliates to research, develop, and commercialize research tools, human therapeutics, or prophylactics derived from iPSCs in a certain range of differentiated cell lineages.

Paris-based Cellectis said that it is the first company in the world to be licensed by iPS Academia Japan under this particular patent portfolio for human therapeutics and prophylactics. It added that its Ectycell subsidiary will use the technology to "engineer these cells and derive consistent lines of robust products both as tools and as therapeutics."

Financial and other terms of the agreements were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.